Publications
- A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes2013 | Publication without faculty affiliation
- Changes associated with lenalidomide treatment in the gene expression profiles of patients with Del(5q)2012 | First Faculty of Medicine
- Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome2011 | First Faculty of Medicine
- Defective cytotoxicity of T lymphocytes in myelodysplastic syndrome2009 | First Faculty of Medicine
- Oxidative DNA damage in bone marrow cells of patients with low-risk myelodysplastic syndrome2009 | First Faculty of Medicine
- MiRNA expression profilig in 5q-syndrome patiens treated with lenalidomidePublication without faculty affiliation
- The response of FLi1, EKLF, TP53 (p53), PU.1, MDM2 gene expression in 5q- syndrome to lenalidomide treatmentPublication without faculty affiliation
- Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin +/- prednisone addition to lenalidomide in refractory or relapsed patients)2018 | First Faculty of Medicine
- TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes2016 | First Faculty of Medicine
- Application of interphase fluorescence in situ hybridisation for the analysis of CD34+ cells in peripheral blood of patients with myelodysplastic syndromes +12016 | First Faculty of Medicine
Loading network view...